Sign in

You're signed outSign in or to get full access.

Matthew Kirkby

Director at BeyondSpring
Board

About Matthew Kirkby

Independent non‑employee director of BeyondSpring Inc. since October 2016; age 55 as of April 1, 2024. He holds an M.A. in Jurisprudence from Pembroke College, University of Oxford, and brings 20+ years of banking experience across London, Hong Kong, and Singapore, including senior roles at HSBC, CIMB, RBS, and ABN AMRO; currently a director/adviser to privately‑held companies . The board has determined he is independent under Nasdaq rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
HSBC (Hong Kong)Head of Corporate Banking, Asia Pacific2015–2016Senior leadership in regional corporate banking
CIMB (Hong Kong)CEO North Asia; Co‑Head of Investment Banking2012–2015Led investment banking across North Asia
Royal Bank of Scotland (Asia Pacific)MD, Global Head of ECM & Corporate Finance; MD, Head of Global Banking APAC2008–2010; 2010–2012Led ECM/corp. finance and regional global banking
ABN AMROVarious positions1999–2007Progressive banking roles

External Roles

OrganizationRolePublic vs PrivateNotes
Various privately‑held companiesDirector/AdviserPrivateCurrently serves in director/adviser capacity; no public company directorships disclosed

Board Governance

  • Committee assignments: Audit Committee member; Compensation Committee chair; Nominating and Corporate Governance Committee member (chair: Dr. Majeti) .
  • Independence: Board determined he is independent under Nasdaq rules .
  • Years of service: Director since October 2016 .
  • Attendance: Board meeting attendance rates not disclosed in available filings; the 2025 proxy is limited to auditor ratification, providing limited governance detail .
  • Director agreements: Director Agreement does not provide termination benefits .

Fixed Compensation

ComponentAmountNotes
Annual cash retainer$40,000Pro‑rated for partial year; effective July 1, 2020
Committee member feesCompensation Committee: $6,000; Nominating & Corporate Governance: $4,000; Audit Committee: $8,000Pro‑rated; chair premiums below
Committee chair feesCompensation Committee: $12,000; Nominating & Corporate Governance: $8,000; Audit Committee: $16,000Pro‑rated
Meeting feesNot disclosedNo per‑meeting fees stated

Performance Compensation

Grant DateAward TypeShares/OptionsExercise PriceExpirationVesting/Notes
01/01/2022Annual option grant10,000$4.5301/01/2032Annual director grant; one‑year vesting
03/07/2022Ad‑hoc committee option grant10,000$1.9903/07/2032Granted for services on ad‑hoc committees
02/10/2023Annual option grant15,000$2.6802/10/2033One‑year vesting; vested by 04/01/2024
05/08/2023One‑time option grant25,000$0.983505/08/2033Additional one‑time grant
12/18/2023Options in lieu of partial 2023 cash comp19,875$0.9912/18/2033Unvested as of 04/01/2024
01/01/2024Annual option grant10,000$0.9001/01/2034Unvested as of 04/01/2024
08/01/2030 (grant year prior)Legacy option5,000$11.0308/01/2030Vested
01/01/2031 (grant year prior)Legacy option10,000$12.2001/01/2031Vested

Performance‑condition framework and clawback:

  • Director equity awards generally service‑based (no revenue/EBITDA/TSR conditions): initial director grants vest over three years; annual director grants vest over one year .
  • Company adopted a clawback policy applicable to Executive Officers; governance‑positive signal though not specific to non‑employee directors .

Other Directorships & Interlocks

CompanyRoleInterlock/Conflict Risk
None disclosed (public company boards)No public interlocks disclosed

Expertise & Qualifications

  • Banking, ECM, and corporate finance senior leadership experience across Asia and Europe; Oxford M.A. in Jurisprudence .
  • Committee leadership (Compensation Committee chair) and membership across Audit and Nominating & Governance .

Equity Ownership

MeasureValueAs‑ofNotes
Total beneficial ownership (shares)81,297April 1, 2024Includes vested options in 60‑day window
Ownership % of outstanding<1%April 1, 2024Based on 39,029,163 shares outstanding; marked “*” in filing
Restricted shares (vested)6,297April 1, 2024Held of record by Mr. Kirkby; all vested
Vested options (exercisable within 60 days)75,000April 1, 20245,000 (08/01/2030), 10,000 (01/01/2031), 10,000 (01/01/2032), 10,000 (03/07/2032), 15,000 (02/10/2033), 25,000 (05/08/2033)
Unvested options29,875April 1, 202419,875 (12/18/2033); 10,000 (01/01/2034)
Shares pledged/hedgedNone disclosedNo pledging/hedging disclosure identified in 20‑F

Governance Assessment

  • Strengths: Independent director; chairs Compensation Committee and sits on Audit and Nominating & Governance, providing cross‑functional oversight . Material personal equity exposure via options and restricted shares aligns incentives with shareholders . Clawback policy adoption (for executives) signals governance focus on accountability .
  • Monitoring points: Use of options in lieu of cash for 2023 director compensation reflects equity‑heavy mix and potential cash conservation; track future balance of cash vs equity and any changes to vesting or award structures . 2025 proxy focuses solely on auditor ratification, providing limited visibility into board attendance and director compensation detail for the current year . Prior auditor report included a going‑concern explanatory paragraph for FY2023; while company‑level, investors may scrutinize compensation and governance discipline under such conditions .
  • Conflicts/related party: No related‑party transactions disclosed involving Mr. Kirkby; Audit Committee oversees approvals of any related‑party transactions .

RED FLAGS

  • Limited AGM agenda (2025 proxy) reduces transparency on director matters (no say‑on‑pay or director elections disclosed this cycle) .
  • Equity in lieu of cash for directors (Dec 2023) warrants monitoring for potential dilution and pay‑mix shifts .
  • Company‑level going‑concern disclosure in prior audit report increases the importance of strong board oversight and cash discipline .

Overall, Kirkby’s independence, committee leadership, and material equity exposure support alignment with shareholders, but investors should monitor award structures (particularly equity in lieu of cash), and seek clarity on attendance and engagement in future filings .